TAYSIDE PRESCRIBER



Tayside DTC Supplement No 86

February 2009

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in January and February 2009

| Medicine | Indication | Local recommendation category | Comments and useful links |
|---|---|---|--|
| Adalimumab solution for injection (Humira ®) - Abbreviated submission | In adolescents with active polyarticular juvenile idiopathic arthritis (13-17 years) in combination with methotrexate | HOSPITAL ONLY Paediatric Rheumatology | SMC advice SPC link |
| Aliskiren tablets (Rasilez®) | Essential hypertension | Not recommended | SMC advice |
| Buprenorphine transdermal patches (BuTrans®) - 3rd Resubmission | Severe opioid responsive pain conditions | Not recommended | SMC advice |
| Doripenem solution for infusion (Doribax®) | Complicated intra-abdominal infections in adults | Pending AMG decision | SMC advice SPC link |
| Etonogestrel/ethinylestradiol vaginal ring (NuvaRing®) - Deferred submission | Contraception | Not recommended | SMC advice |
| Etravirine tablets (Intelence®) | Treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients | Not recommended | SMC advice |
| Extended release epidural morphine (Depodur®) | Post-operative pain following major orthopaedic, abdominal or pelvic surgery | Not recommended | SMC advice |
| Fentanyl buccal tablets (Effentora®) - Deferred submission | Breakthrough pain (BTP) in adults using opioid therapy for chronic cancer pain | Pending specialist feedback | SMC advice SPC link |
| Fentanyl sublingual tablets (Abstral®) - Abbreviated submission | Breakthrough pain(BTP) in adults using opioid therapy for chronic cancer pain | Pending specialist feedback | SMC advice SPC link |
| Lacosamide tablets, syrup, & solution for infusion (Vimpat®) | Add- on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years or older | Pending specialist feedback | SMC advice SPC link |
| Lapatinib tablets (Tyverb®) | Advanced or metastatic breast cancer | Not recommended | SMC advice |
| Pemetrexed powder for concentrate for solution for infusion (Alimta®) | In combination with cisplatin for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | Not recommended | SMC advice |
| Salmeterol/fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler [®]) - Resubmission | Symptomatic treatment of patients with chronic obstructive airways disease (COPD) with FEV ₁ 50% to <60% of predicted | Not recommended | SMC advice |
| Stiripentol capsules, powder for oral solution (Diacomit®) | Use with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) | Not recommended | SMC advice SMC advises that patients continue to receive treatment and are not switched to alternative therapies if it is currently proving clinically effective |
| Sugammadex solution for injection (Bridion®) | Immediate reversal of rocuronium-induced neuromuscular blockade | HOSPITAL ONLY Theatres and Anaesthetics | SMC advice SPC link |

| Thalidomide capsules (Thalidomide Pharmion®) | In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged 65 years or over or ineligible for high dose chemotherapy | Pending OHMMG decision | SMC advice SPC link |
|--|--|------------------------|------------------------|
| Zoledronic acid 5mg solution for infusion (Aclasta®) - <i>Non-submission</i> | Osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture | Not recommended | SMC advice |

Updates from previous SMC advice

| Medicine | Indication | Local recommendation category | Comments and useful links |
|--|--|---|---|
| Rivaroxaban tablets (Xarelto®) | Prevention of VTE in adults undergoing elective hip or knee replacement surgery | HOSPITAL ONLY (Orthopaedic department) Local treatment protocol available | SMC advice SPC link The full treatment course will be supplied by the hospital pharmacy prior to discharge |
| Atazanavir capsules (Reyataz [®]) | In treatment naïve HIV-1 infected adults in combination with other antiretrovirals | HOSPITAL ONLY (HIV clinic) | SMC advice SPC link Second line protease inhibitor if unable to tolerate Kaletra® or problems with hyperlipidaemia |
| Tenofovir disoproxil fumarate tablets (Viread [®]) | Treatment of chronic hepatitis B in adults with compensated liver disease | HOSPITAL ONLY (Hepatitis B Clinic) | SMC advice SPC link First line treatment for Hepatitis B |

Click here for **January** and **February** SMC briefing note

Melatonin use in sleep disorders in children

A shared care agreement is in the final stages of development. It will shortly be presented to the Policy Group for consideration.

TAPG Update

| | TAPG section | Drug(s)/topic | Changes |
|-----|---------------------------------|----------------------------|---|
| 6.6 | Drugs affecting bone metabolism | Bisphosphonates | Statement added at end of section about the relative risk of atrial fibrillation with some bisphosphonates |
| 6.7 | Other Endocrine Drugs | Dopamine-receptor agonists | New section added. Cabergoline, bromocriptine and quinagolide listed as main entries in section 6.7.1 Risk of cardiac fibrosis with ergot-derived dopamine agonists noted with link to MHRA advice. |

^{*}SMC accepted

Forthcoming SMC Advice

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use.

CLICK HERE for access to the Medicines Governance section of the Pharmacy Staffnet site.